Novo Nordisk Company Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.
The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space.
Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Country | Denmark |
| Founded | 1923 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 77,349 |
| CEO | Maziar Doustdar |
Contact Details
Address: Novo Alle 1 Bagsvaerd, 2880 Denmark | |
| Phone | 45 44 44 88 88 |
| Website | novonordisk.com |
Stock Details
| Ticker Symbol | NONOF |
| Exchange | OTCMKTS |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0060534915 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Maziar Mike Doustdar | President, Chief Executive Officer, Executive Vice President of International Operations and Member of the Management Board |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer and Member of the Management Board |
| Henrik Ehlers Wulff | Executive Vice President of CMC and Product Supply and Member of the Management Board |
| Ludovic Helfgott | Executive Vice President of Product and Portfolio Strategy and Member of Management Board |
| Dr. Martin Holst Lange | Executive Vice President of Development, CSO and Member of the Management Board |
| Tania Sabroe | Executive Vice President of People, Organisation and Corporate Affairs and Member of Management Board |
| David S. Moore | Executive Vice President of US Operations and Member of Management Board |
| Thilde Hummel Bogebjerg | Executive Vice President of Quality, IT and Environmental Affairs and Member of Management Board |
| Jacob Martin Wiborg Rode | Head of Investor Relations |
| John F. Kuckelman | Group General Counsel |